3,5-disubstituted pyridines with potent activity against drug-resistant <i>Mycobacterium tuberculosis</i> clinical isolates.

ABSTRACT: Aim: We designed and synthesized a series of compounds with a 3,5-disubstituted pyridine moiety and evaluated them against Mycobacterium tuberculosis (Mtb) and drug-resistant Mtb clinical isolates.Methodology: A library of 3,5-disubstituted pyridine was synthesized. The compounds were screened for activity against M. tuberculosis H37Rv. The optimal substitutions needed for the activity were identified through structure-activity relationship (SAR) studies.Results: From the screening studies, compounds 24 and 26 were identified as potent members of this series with Minimum Inhibitory Concentration (MIC) of 1.56 μg/ml against M. tuberculosis H37Rv. These compounds did not show any inhibition against a panel of ESKAPE pathogens at >50 μg/

SUBMITTER: Sangu KG 

PROVIDER: S-EPMC11622763 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature